Humacyte (HUMA) news
Recent news
Humacyte confirms plans for Atev supplemental BLA filing
AInvest Wire · 7d agoHumacyte - to file supplemental BLA with FDA for Atev in dialysis access in November 2026
AInvest Wire · 7d agoHumacyte Q2 cash & investments USD 80.3 million
Humacyte, Inc. (Nasdaq: HUMA) reported cash and cash equivalents of $114.6 million as of June 30, 2023. This figure reflects the company’s financial position during the second quarter of 2023, prior to its commercial launch of Symvess in late February 2025. By March 31, 2025, the company’s cash and…
AInvest Wire · Aug 12, 2026Humacyte Inc: TD Cowen cuts target price to $1.25 from $1.5
TD Cowen has revised its price target for Humacyte Inc. (NASDAQ:HUMA) to $1.25 from $1.50, while maintaining a Buy rating on the stock. The adjustment follows the firm’s reassessment of the company’s financial performance and near-term challenges. Humacyte reported its first-quarter 2026 results,…
AInvest Wire · Jun 17, 2026HUMACYTE, INC.: H.C. Wainwright raises target price to $4 from $3
H.C. Wainwright has raised its price target for Humacyte, Inc. (NASDAQ:HUMA) to $4.00 per share from $3.00, while maintaining its "Buy" rating . The stock currently trades at $1.13, reflecting a 17.65% increase year-to-date, although it remains down nearly 40% over the past year. The firm cited the…
AInvest Wire · Jun 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.